SZN-1326, A TETRAVALENT, BISPECIFIC ANTIBODY DEVELOPED FOR THE TREATMENT OF ULCERATIVE COLITIS, HAS A FAVORABLE PROFILE IN 13-WEEK GLP TOXICITY STUDIES

Anh Diep  1     Jay Tibbitts     Stanley Roberts  2     Peter Stathis     William Nowatzke     Maureen Newman     Trudy Vanhove    
1 Surrozen, Inc., South San Francisco, United States
2 SAR Safety Assessment, Northbrook, United States

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing